Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Pili

Showing results (121-130 of 198) with videos related to

Pageof 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2007
Platelets take up the monoclonal antibody bevacizumabHenk M W Verheul, Martijn P J Lolkema, David Z Qian, et al.
Urology|October 16, 2013
Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancerShabnam Rehman, Alice Crane, Rakeeba Din, et al.
British Journal of Cancer|November 1, 2019
Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitorsGiosue Scognamiglio, Annarosaria De Chiara, Antonina Parafioriti, et al.
Urologic Oncology|September 22, 2014
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)Andrew J Armstrong, Reza Kaboteh, Michael A Carducci, et al.
Cancer|June 19, 2009
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 studyDavid J Vaughn, Sandy Srinivas, Walter M Stadler, et al.
Free Radical Biology & Medicine|August 6, 2011
Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cellsPiergiorgio Pettazzoni, Eric Ciamporcero, Claudio Medana, et al.
Clinical Genitourinary Cancer|October 29, 2015
Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder CarcinomaVenkata K Pokuri, Johar R Syed, Zhengyu Yang, et al.
Investigational New Drugs|May 26, 2010
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)Michael R Harrison, Noah M Hahn, Roberto Pili, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 7, 2009
Concordance of cancer patients' function, symptoms, and supportive care needsClaire F Snyder, Elizabeth Garrett-Mayer, Amanda L Blackford, et al.
Clinical Genitourinary Cancer|May 27, 2017
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805])Roberto Pili, Opeyemi Jegede, Michael A Carducci, et al.
Pageof 20

Showing results (121-130 of 198) with videos related to

Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2007
Platelets take up the monoclonal antibody bevacizumabHenk M W Verheul, Martijn P J Lolkema, David Z Qian, et al.
Urology|October 16, 2013
Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancerShabnam Rehman, Alice Crane, Rakeeba Din, et al.
British Journal of Cancer|November 1, 2019
Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitorsGiosue Scognamiglio, Annarosaria De Chiara, Antonina Parafioriti, et al.
Urologic Oncology|September 22, 2014
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)Andrew J Armstrong, Reza Kaboteh, Michael A Carducci, et al.
Cancer|June 19, 2009
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 studyDavid J Vaughn, Sandy Srinivas, Walter M Stadler, et al.
Free Radical Biology & Medicine|August 6, 2011
Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cellsPiergiorgio Pettazzoni, Eric Ciamporcero, Claudio Medana, et al.
Clinical Genitourinary Cancer|October 29, 2015
Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder CarcinomaVenkata K Pokuri, Johar R Syed, Zhengyu Yang, et al.
Investigational New Drugs|May 26, 2010
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)Michael R Harrison, Noah M Hahn, Roberto Pili, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 7, 2009
Concordance of cancer patients' function, symptoms, and supportive care needsClaire F Snyder, Elizabeth Garrett-Mayer, Amanda L Blackford, et al.
Clinical Genitourinary Cancer|May 27, 2017
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805])Roberto Pili, Opeyemi Jegede, Michael A Carducci, et al.
Pageof 20